Pharma BD Deal Intelligence
Lilly's $1.1B swing at Dupixent's turf: buying Dermira added Phase 3 IL-13 antibody lebrikizumab and marketed Qbrexza to a Taltz/Olumiant stack, but at deal time lebrikizumab was still unproven in atopic dermatitis Phase 3.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly is buying Dermira for $1.1 billion in cash to acquire lebrikizumab, a Phase 3 IL-13 antibody for atopic dermatitis. The acquisition extends Lilly's…
Eli Lilly is paying $1.1 billion for Dermira to add lebrikizumab to its immunology pipeline, the company said Friday. The Phase 3 IL-13 antibody is positioned…
Sep 13, 2024: FDA approved Lilly's EBGLYSS (lebrikizumab-lbkz) for adults and children 12 years and older (>=88 lbs) with moderate-to-severe atopic dermatitis…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Eli Lilly agreed to acquire Dermira for $18.75/share in cash, ~$1.1B total. The deal added lebrikizumab, a Phase 3 IL-13 monoclonal antibody for atopic dermatitis, plus marketed product Qbrexza for hyperhidrosis. Bolstered Lilly's immunology/dermatology pipeline alongside Taltz and Olumiant.
Assessment window: 5yr post-close.
16.5M US cases/yr · $9.0B Global AD biologics + JAK market 2022 · ~$1.1B Total deal value (cash, $18.75/share)
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, eczematous lesions, xerosis, and disrupted epidermal barrier function. AD affects approximately 16.5 million U.S. adults (7.3% prevalence) and 9.6 million U.S. children, with roughly 6.6 million adult patients carrying moderate-to-severe disease eligible for systemic biologic therapy. The pathophysiology centers on Th2-skewed cytokine drive (IL-4, IL-13, IL-31, TSLP) atop genetic barrier defects (filaggrin loss-of-function). IL-13 is the dominant effector cytokine in AD lesional skin, validated as a tractable therapeutic target by the success of dupilumab (anti-IL-4Rα blocking IL-4 and IL-13 signaling). The AD biologics and JAK inhibitor market exploded after dupilumab's 2017 launch and reached approximately $9 billion globally by 2022. WAC pricing for AD systemic biologics ranges $40,000-$60,000 per patient per year. Dermira's lead asset lebrikizumab (humanized anti-IL-13 mAb) was in Phase 3 ADvocate1/ADvocate2 monotherapy and ADhere combination trials at the time of acquisition, positioned as a high-affinity IL-13-selective alternative to dupilumab.
The AD systemic landscape is anchored by Dupixent (dupilumab, Sanofi/Regeneron), the entrenched anti-IL-4Rα franchise leader generating over $8B in 2022 global sales across AD, asthma, eosinophilic esophagitis, prurigo nodularis, and CRSwNP. Adbry/Adtralza (tralokinumab, LEO Pharma, anti-IL-13) was first selective IL-13 antibody approved (FDA Dec-2021) and serves as the closest peer comparator for lebrikizumab. Lebrikizumab (Dermira/Lilly, anti-IL-13) reads out positive Phase 3 ADvocate1/2 in 2022 and was approved as Ebglyss in EU/UK in 2023, with U.S. approval delayed by manufacturing CRL until late-2024. Oral JAK inhibitors include Rinvoq (upadacitinib, AbbVie), Cibinqo (abrocitinib, Pfizer), and Olumiant (baricitinib, Lilly/Incyte; not approved for AD in U.S.). Pipeline biologics include nemolizumab (anti-IL-31RA, Galderma/Maruho), rocatinlimab (anti-OX40, Kyowa Kirin/Amgen), and amlitelimab (anti-OX40L, Sanofi). Topical agents include Eucrisa, Opzelura (ruxolitinib cream, Incyte), and Vtama (tapinarof, Dermavant). Lilly's lebrikizumab acquisition positioned the company to compete head-to-head with Dupixent in the largest dermatology biologic franchise.
The two monotherapy Phase 3 trials of lebrikizumab in moderate-to-severe atopic dermatitis met their Week-16 primary endpoint and all key secondary endpoints (IGA 0/1, EASI-75, itch NRS), with response maintained to 52 weeks - clinical validation of the asset Lilly acquired with Dermira.
FDA issued a CRL citing inspection findings at a third-party contract manufacturer of the mAb drug substance. The letter raised no concerns about the clinical data, safety, or label, but delayed U.S. approval of the lead acquired asset.
FDA approved EBGLYSS for adults and children 12+ with moderate-to-severe atopic dermatitis, giving Lilly its targeted IL-13 entry against Dupixent ~4.5 years after the $1.1B Dermira buyout closed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Dermira Inc. (this deal) | 2020 | $1.1B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2020 deals · Eli Lilly and Company deals · Dermatology deals